Skip to main content

Table 4 Recent Prospective Trials of Recurrent High-grade Glioma

From: Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience

Treatment Author, Year Regimen Median Dose(Gy) Sample Size(N) MST (Months)
Systemic Therapy Reardon, 2017 [8] Nivolumab vs BVZ N/A Nivo = 184 BVZ = 185 9.8 vs 10.0
Wick, 2017 [9] Lomustine +BVZ vs Lomustine N/A L + BVZ = 228 L = 149 9.1 vs 8.6
Friedman, 2009 [10] BVZ vs BVZ + CPT11 N/A BVZ = 85 BVZ + CPT11 = 82 9.2 vs 8.7
TTF Stupp, 2012 [12] TTField vs Chemotherapy N/A TTF = 120 Chemotherapy = 117 6.6 vs 6
HSRT Clarke, 2017 [13] HSRT+BVZ 30 15 12.5
Miwa, 2014 [14] HSRT+TMZ 30 21 12.0
Wuthrick, 2014 [15] HSRT+Sunitinib 35 11 12.7(GBM)
  1. Abbreviations: TTF Tumor Treatment Field, HSRT Hypofractionated stereotactic radiotherapy, BVZ Bevacizumab, TMZ Temozolomide, GBM Glioblastoma Multiforme